Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial

被引：6
|
作者：
Baize, N. [1 ]
Monnet, I. [2 ]
Greillier, L. [3 ]
Geier, M. [4 ]
Lena, H. [5 ]
Janicot, H. [6 ]
Vergnenegre, A. [7 ]
Crequit, J. [8 ]
Lamy, R. [9 ]
Auliac, J. B. [10 ]
Le Treut, J. [11 ]
Le Caer, H. [12 ]
Gervais, R. [13 ]
Dansin, E. [14 ]
Madroszyk, A. [15 ]
Renault, P. [16 ]
Legarff, G. [17 ]
Schott, R. [18 ]
Saulnier, P. [1 ]
Chouaid, C. [2 ]
机构：
[1] CHU Angers, Angers, France
[2] Chi Creteil, Pneumol, Creteil, France
[3] Ap Marseille, Serv Oncol Multidisciplinaire & Innovat Therapeut, Marseille, France
[4] CHU Brest, Inst Cancerol & Hematol, Brest, France
[5] CHU Rennes, Serv Pneumol, Rennes, France
[6] Hop Montpied, CHU, Clermont Ferrand, France
[7] CHU Limoges, Limoges, France
[8] Ch Beauvais, Beauvais, France
[9] Ch Bretagen Sud, Lorient, France
[10] Ctr Hosp F Quesnay, Mantes La Jolie, France
[11] Ctr Hosp Pays Aix, Aix En Provence, France
[12] Ctr Hosp St Brieuc, St Brieuc, France
[13] Ctr Francois Baclesse, Caen, France
[14] Ctr Oscar Lambret, Lille, France
[15] Inst Paoli Calmette, Marseille, France
[16] Ch Pau, Pau, France
[17] Ctr Hosp St Brieux, St Brieux, France
[18] Clcc Paul Strauss, Strasbourg, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Small Cell Lun Cancer; second line; phase; 3; trial;
D O I：
10.1016/j.jtho.2019.08.490
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA15.02
引用
收藏
页码：S246 / S246
页数：1
相关论文
共 50 条
  • [31] Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer
    Garst, Jennifer
    Buller, Richard
    Lane, Stephen
    Crawford, Jeffrey
    CLINICAL LUNG CANCER, 2005, 7 (03) : 190 - 196
  • [32] A randomized multicenter phase III trial of topotecan monotherapy versus topotecan plus etoposide versus topotecan plus gemcitabine for second-line treatment of recurrent ovarian cancer.
    Sehouli, J.
    Sommer, H.
    Klare, P.
    Stauch, M.
    Zeimet, A.
    Paulenz, A.
    Steck, T.
    Riedel, H.
    Keil, E.
    Stengel, D.
    Kuznik, A.
    Lichtenegger, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 263S - 263S
  • [33] CARDIAC SAFETY OF AMRUBICIN IN A RANDOMIZED PHASE 3 TRIAL OF AMRUBICIN VS TOPOTECAN AS SECOND-LINE TREATMENT FOR SMALL CELL LUNG CANCER (SCLC)
    Spigel, David R.
    Von Pawel, Joachim
    Jotte, Robert
    Socinski, Mark A.
    O'Brien, Mary E. R.
    Mcnally, Richard
    Renschler, Markus
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S309 - S309
  • [34] A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer
    Schmittel, A
    von Weikersthal, LF
    Sebastian, M
    Martus, P
    Schulze, K
    Hortig, P
    Reeb, M
    Thiel, E
    Keilholz, U
    ANNALS OF ONCOLOGY, 2006, 17 (04) : 663 - 667
  • [35] Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review
    Ushijima, Futoshi
    Hase, Tetsunari
    Yamashita, Yuki
    Kim, Hangsoo
    Shimokata, Tomoya
    Kondo, Chiaki
    Sato, Tomonori
    Baba, Tomoya
    Watanabe, Shohei
    Futamura, Keisuke
    Ando, Yuichi
    Mizuno, Masashi
    Ishii, Makoto
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2024, 13 (02) : 88 - 92
  • [36] Preliminary results of a randomised comparative phase III trial of topotecan versus CAV as second-line therapy of small cell lung cancer
    Clarke, P
    Schiller, JH
    VonPawel, J
    Kleisbauer, JP
    Dobbs, T
    Chrysson, N
    Dane, G
    Hudson, I
    DeWitte, M
    Fields, SZ
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1032 - 1032
  • [37] Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients
    Schmittel, Alexander
    Knoedler, Maren
    Hortig, Patricia
    Schulze, Karsten
    Thiel, Eckhard
    Keilholz, Ulrich
    LUNG CANCER, 2007, 55 (01) : 109 - 113
  • [38] Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer:: A Randomized phase III trial
    Hermes, Andreas
    Bergman, Bengt
    Bremnes, Roy
    Ek, Lars
    Fluge, Sverre
    Sederholm, Christer
    Sundstrom, Stein
    Thaning, Lars
    Vilsvik, Jan
    Aasebo, Ulf
    Soerenson, Sverre
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) : 4261 - 4267
  • [39] A randomized phase III study of cisplatin ( CDDP), etoposide (ETOP) and irinotecan versus topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer (SCLC): Japan Clinical Oncology Group study} JCOG0605
    Goto, Koichi
    Ohe, Yuichiro
    Seto, Takashi
    Takahashi, Toshiaki
    Nakagawa, Kazuhiko
    Yamamoto, Noboru
    Yokoyama, Akira
    Takeda, Koji
    Nishio, Makoto
    Mori, Kiyoshi
    Satouchi, Miyako
    Hida, Toyoaki
    Kudoh, Shinzoh
    Nogami, Naoyuki
    Imamura, Fumio
    Kiura, Katsuyuki
    Okamoto, Hiroaki
    Sawa, Toshiyuki
    Shibata, Taro
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy
    Jotte, Robert
    Conkling, Paul
    Reynolds, Craig
    Galsky, Matthew D.
    Klein, Leonard
    Fitzgibbons, James F.
    McNally, Richard
    Renschler, Markus F.
    Oliver, Jennifer W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (03) : 287 - 293
12345